These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 564941)

  • 1. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.
    Fogelman I; Bessent RG; Turner JG; Citrin DL; Boyle IT; Greig WR
    J Nucl Med; 1978 Mar; 19(3):270-5. PubMed ID: 564941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diphosphonates in the evaluation of metabolic bone disease.
    Fogelman I; Smith ML
    Clin Rheumatol; 1982 Mar; 1(1):41-4. PubMed ID: 6236012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Measurement of 24-hr whole-body retention of 99mTc-MDP with a thyroid uptake probe (author's transl)].
    Seto H; Kakishita M; Futatsuya R
    Radioisotopes; 1981 May; 30(5):263-7. PubMed ID: 6458840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radionuclide imaging in metabolic and systemic skeletal diseases.
    McAfee JG
    Semin Nucl Med; 1987 Oct; 17(4):334-49. PubMed ID: 3317847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Whole-body retention of 99mTc-methylene diphosphonate in skeletal diseases].
    Zorn-Bopp E; Büll U; Münzing W; Lang P; Moser EA
    Nuklearmedizin; 1983 Feb; 22(1):24-30. PubMed ID: 6223277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone scintigraphy and metabolic disorders.
    Marì C; Catafau A; Carriò I
    Q J Nucl Med; 1999 Sep; 43(3):259-67. PubMed ID: 10568141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of 24-hour whole-body retention of Tc-99mMDP with a thyroid uptake probe: quantitative assessment of metabolic and metastatic bone diseases.
    Seto H; Futatsuya R; Ihara F; Kamei T; Furumoto N; Ishizaki Y; Hada M; Kakishita M
    Radiat Med; 1984; 2(2):87-92. PubMed ID: 6240671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication.
    Fogelman I; Pearson DW; Bessent RG; Tofe AJ; Francis MD
    J Nucl Med; 1981 Oct; 22(10):880-3. PubMed ID: 6457135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renal failure and metabolic diseases upon bone scanning in children.
    Schümichen C
    Ann Radiol (Paris); 1983; 26(6):498-504. PubMed ID: 6316830
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone scintigraphy in renal osteodystrophy.
    de Graaf P; Schicht IM; Pauwels EK; te Velde J; de Graeff J
    J Nucl Med; 1978 Dec; 19(12):1289-96. PubMed ID: 104017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent.
    Degrossi OJ; Oliveri P; García del Río H; Labriola R; Artagaveytía D; Degrossi EB
    J Nucl Med; 1985 Oct; 26(10):1135-9. PubMed ID: 4045556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of technetium-99m diphosphonate.
    Castronovo FP; Guiberteau MJ; Berg G; McKusick KA; Callahan RJ; Potsaid MS
    J Nucl Med; 1977 Aug; 18(8):809-14. PubMed ID: 874170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bone scan in clinical practice.
    Fogelman I; Boyle IT
    Scott Med J; 1980 Jan; 25(1):45-9. PubMed ID: 7209498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technetium-99m-labeled methylene diphosphonate and hydroxyethylidine diphosphonate--biologic and clinical comparison: concise communication.
    Rudd TG; Allen DR; Smith FD
    J Nucl Med; 1979 Aug; 20(8):821-6. PubMed ID: 120422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical assessment of bone scan quantitation (bone to soft tissue ratios) in the diagnosis of metabolic bone disease.
    Fogelman I; Bessent RG; Gordon D
    Eur J Nucl Med; 1981 Mar; 6(3):93-7. PubMed ID: 6783412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with two simple methods of measurement of 99mTc-methylene diphosphonate body retention in bone disease.
    Reschini E; Ulivieri FM; Ortolani S
    J Nucl Biol Med (1991); 1991; 35(3):123-30. PubMed ID: 1816867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication.
    Fogelman I; Citrin DL; McKillop JH; Turner JG; Bessent RG; Greig WR
    J Nucl Med; 1979 Feb; 20(2):98-101. PubMed ID: 430202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative radionuclide scanning in metabolic bone disease.
    Meindok H; Rapoport A; Oreopoulos DG; Rabinovich S; Meema HE; Meema S
    Nucl Med Commun; 1985 Mar; 6(3):141-8. PubMed ID: 3158846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis of metabolic bone diseases: radiographic diagnosis].
    Inoue T; Kushida K
    Nihon Rinsho; 1986 Nov; 44(11):2443-51. PubMed ID: 3546798
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone uptake of 99mTc-MDP in man: its relationship with local blood flow.
    Vattimo A; Martini G; Pisani M
    J Nucl Med Allied Sci; 1982; 26(3):173-9. PubMed ID: 6184461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.